Floatz logo

Ixekizumab

Psoriasis

Eli Lilly and Companymonoclonal_antibodyPhase 3Active
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
89/ 100

Competitive context

12 Active assets in the Psoriasis cohort.

Asset / SponsorPhaseRating
1-235-TUMOR NECROSIS FACTOR RECEPTOR (HUMAN) FUSION PROTEIN WITH 236-467-IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN FC FRAGMENT), DIMER
Amgen
Phase 4BBB
Calcipotriene
Hospital Universitario Dr. Jose E. Gonzalez
Phase 4BBB
Tirzepatide
Eli Lilly and Company
Phase 4BBB
Semaglutide
Hospital Universitario Dr. Jose E. Gonzalez
Phase 4BBB
cp-690,550
Pfizer
Phase 3BBB

View all 28 →

Same molecule, other indications

Ixekizumab is also rated in:

psoriatic arthritisDormant
BB
Indicative ·
64 / 100
View asset →
obesity disorderDormant
B
Indicative ·
56 / 100
View asset →
major depressive disorderDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →